Oxaliplatin

Catalog No.S1224 Batch:S122411

Print

Technical Data

Formula

C8H14N2O4Pt
Molecular Weight 397.29 CAS No. 61825-94-3
Solubility (25°C)* In vitro Water 2 mg/mL (5.03 mM)
Ethanol Insoluble
 
In vivo (Add solvents to the product individually and in order)
Clear solution
saline
2.000mg/ml Taking the 1 mL working solution as an example, add 2 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Oxaliplatin is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]

Protocol (from reference)

Cell Assay:

[4]
  • Cell lines

    RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines

  • Concentrations

    ~100 μM

  • Incubation Time

    48 hours

  • Method

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
Animal Study:

[6]
  • Animal Models

    Human hepatocellular carcinoma xenografts HCCLM3

  • Dosages

    10 mg/kg

  • Administration

    A weekly i.p. injection

Customer Product Validation

Data from [ J Proteomics , 2014 , 10.1016/j.jprot.2014.10.009 ]

Data from [ Optical Methods for Tumor Treatment and Detection , 2013 , 10.1117/12.2010730 ]

, 2013 , Dr. Edita Aksamitiene from Thomas Jefferson University

Data from [ , , Cell, 2017, 170(3):548-563.e16 ]

Selleck's Oxaliplatin has been cited by 271 publications

Activation of lysosomal iron triggers ferroptosis in cancer [ Nature, 2025, 10.1038/s41586-025-08974-4] PubMed: 40335696
Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink [ Adv Sci (Weinh), 2025, 12(10):e2411769] PubMed: 39748450
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma [ J Exp Clin Cancer Res, 2025, 44(1):13] PubMed: 39810240
Unveiling radiobiological traits and therapeutic responses of BRAFV600E-mutant colorectal cancer via patient-derived organoids [ J Exp Clin Cancer Res, 2025, 44(1):92] PubMed: 40069844
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response [ Mol Syst Biol, 2025, 21(3):231-253] PubMed: 39838187
CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis [ Oncogene, 2025, 10.1038/s41388-025-03337-9] PubMed: 40089640
USP14 inhibits mitophagy and promotes tumorigenesis and chemosensitivity through deubiquitinating BAG4 in microsatellite instability-high colorectal cancer [ Mol Med, 2025, 31(1):163] PubMed: 40316942
USP1 promotes pancreatic cancer progression and autophagy by deubiquitinating ATG14 [ J Biol Chem, 2025, 301(3):108190] PubMed: 39814232
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase [ Lipids Health Dis, 2025, 24(1):14] PubMed: 39825408
NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer [ World J Gastroenterol, 2025, 31(11):100785] PubMed: 40124268

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.